🏛️ Verified NIH Record • Updated 2025-09-08
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer (NCT03414684)
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Dana-Farber Cancer Institute
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: * Carboplatin * Nivolumab
Who can join: Review the eligibility criteria below.
Location: The Stamford Hospital — Stamford, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- The Stamford Hospital — Stamford, Connecticut
- Eastern Maine Medical Center — Bangor, Maine
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- St. Elizabeth's Medical Center — Boston, Massachusetts
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center — Milford, Massachusetts
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital — South Weymouth, Massachusetts
- Dana-Farber/New Hampshire Oncology-Hematology — Londonderry, New Hampshire
- Ohio State University — Columbus, Ohio
- University of Vermont Medical Center — Burlington, Vermont
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.